NCD opened for CardioDynamics
This article was originally published in The Gray Sheet
Executive Summary
Firm hopes CMS will expand coverage of its thoratic electrical bioimpedance (TEB) devices for the management of all patients with hypertension. Coverage for the management of drug-resistant hypertension, defined by non-response to three or more medications, is at the discretion of local contractors, while other forms of hypertension are non-covered. CardioDynamics cites recent data from its multi-centered, randomized CONTROL trial as evidence that its BioZ impedance cardiography technology leads to greater reduction in blood pressure than standard care (1"The Gray Sheet" July 4, 2005, p. 15). An initial comment period on the decision ends March 30, with a proposed decision due by Aug. 28...